Company Profile

Genelabs Technologies Inc (AKA: Gene Labs, Inc.)
Profile last edited on: 3/5/2020      CAGE: 0K7W3      UEI: ----------

Business Identifier: Drug discovery capabilities that can support various research and development projects
Year Founded
1984
First Award
1984
Latest Award
1998
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

505 Penobscot Drive
Redwood City, CA 94063
   (650) 369-9500
   info@genelabs.com
   www.genelabs.com
Location: Multiple
Congr. District: 14
County: San Mateo

Public Profile

In October 2008, GlaxoSmithKline plc acquired Genelabs Technologies. Previously called Gene Labs, Inc, the firm had developed Prestara to treat lupus, a condition for which a new drug has not been approved in the US for more than five decades. The company first submitted Prestara for FDA approval in 2000 and had been working with the agency from that point to gather enough clinical evidence to win a regulatory green light for the drug. In addition to its efforts with Prestara, the company has licensed development of a hepatitis E vaccine to GlaxoSmithKline and is has a drug discovery program looking for new compounds to treat hepatitis C. The firm is working with Novartis on some hepatitis C candidates. The firm has focused on building drug discovery capabilities that can support various research and development projects. Genelabs has concentrated these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : GNLB
IP Holdings
100-149

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1998 1 NIH $101,458
Project Title: Novel Putative Asthma/Atopy Genes in Human Chromosome 5
1996 1 NIH $93,852
Project Title: Development Of Immunoassay For Hepatitis G Virus (HGV)
1994 1 NIH $78,960
Project Title: Development of a cell culture system for HIV infection
1994 1 NIH $77,900
Project Title: Recombinant HEV-like particles as a potential vaccine
1992 2 Army $597,182
Project Title: Assay Development of Diagnostic Tests for Hepatitis E.

Key People / Management

  H H Haight -- President

  Alexander S Belyaev

  Thomas W Bruice -- Business Official

  Chin-Hai Chang

  Irene Chow

  Gregory M Dolganov

  Cynthia A Edwards

  Kirk E Fry

  Kou M Hwamg

  Jungsuh Kim

  James W Larrick

  Michael Lovett

  Rich Meyer -- Business Official

  Michael Piatak

  Gregory R Reyes

  James A D Smith

  Albert W Tam

  John M Wages -- Co-Founder, Director of Molecular Biology & Genetics

  Patrice Yarbough

Company News

There are no news available.